329 related articles for article (PubMed ID: 19840887)
1. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.
Fleming GF; Sill MW; Darcy KM; McMeekin DS; Thigpen JT; Adler LM; Berek JS; Chapman JA; DiSilvestro PA; Horowitz IR; Fiorica JV
Gynecol Oncol; 2010 Jan; 116(1):15-20. PubMed ID: 19840887
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
[TBL] [Abstract][Full Text] [Related]
3. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
Grushko TA; Filiaci VL; Mundt AJ; Ridderstråle K; Olopade OI; Fleming GF;
Gynecol Oncol; 2008 Jan; 108(1):3-9. PubMed ID: 17945336
[TBL] [Abstract][Full Text] [Related]
4. Limited clinical benefit from trastuzumab in recurrent endometrial cancer: two case reports.
Vandenput I; Vanden Bempt I; Leunen K; Neven P; Berteloot P; Moerman P; Vergote I; Amant F
Gynecol Obstet Invest; 2009; 67(1):46-8. PubMed ID: 18843183
[TBL] [Abstract][Full Text] [Related]
5. Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma.
Koskas M; Depreeuw J; Moens S; Annibali D; Cuppens T; Moerman P; Lambrechts D; Amant F
Anticancer Res; 2016 Oct; 36(10):5381-5384. PubMed ID: 27798902
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu.
Santin AD; Bellone S; Roman JJ; McKenney JK; Pecorelli S
Int J Gynaecol Obstet; 2008 Aug; 102(2):128-31. PubMed ID: 18555254
[TBL] [Abstract][Full Text] [Related]
7. Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study" recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010).
Santin AD
Gynecol Oncol; 2010 Jul; 118(1):95-6; author reply 96-7. PubMed ID: 20172595
[No Abstract] [Full Text] [Related]
8. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2).
Lumish M; Chui MH; Zhou Q; Iasonos A; Sarasohn D; Cohen S; Friedman C; Grisham R; Konner J; Kyi C; Rubinstein M; Troso-Sandoval T; Aghajanian C; Makker V
Gynecol Oncol; 2024 Mar; 182():75-81. PubMed ID: 38262242
[TBL] [Abstract][Full Text] [Related]
9. HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
Shen S; Ma W; Brown D; Da Cruz Paula A; Zhou Q; Iaosonos A; Tessier-Cloutier B; Ross DS; Troso-Sandoval T; Reis-Filho JS; Abu-Rustum N; Zhang Y; Ellenson LH; Weigelt B; Makker V; Chui MH
Mod Pathol; 2023 Nov; 36(11):100299. PubMed ID: 37558129
[TBL] [Abstract][Full Text] [Related]
10. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.
Growdon WB; Groeneweg J; Byron V; DiGloria C; Borger DR; Tambouret R; Foster R; Chenna A; Sperinde J; Winslow J; Rueda BR
Gynecol Oncol; 2015 Apr; 137(1):160-6. PubMed ID: 25602714
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
[TBL] [Abstract][Full Text] [Related]
12. Decreased HER2 expression in endometrial cancer following anti-HER2 therapy.
Chui MH; Brown DN; Da Cruz Paula A; da Silva EM; Momeni-Boroujeni A; Reis-Filho JS; Zhang Y; Makker V; Ellenson LH; Weigelt B
J Pathol; 2024 Feb; 262(2):129-136. PubMed ID: 38013631
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Vogel CL; Cobleigh MA; Tripathy D; Gutheil JC; Harris LN; Fehrenbacher L; Slamon DJ; Murphy M; Novotny WF; Burchmore M; Shak S; Stewart SJ; Press M
J Clin Oncol; 2002 Feb; 20(3):719-26. PubMed ID: 11821453
[TBL] [Abstract][Full Text] [Related]
14. Does Specimen Type Have an Impact on HER2 Status in Endometrial Serous Carcinoma? Discordant HER2 Status of Paired Endometrial Biopsy and Hysterectomy Specimens in the Presence of Frequent Intratumoral Heterogeneity.
Rottmann D; Assem H; Matsumoto N; Wong S; Hui P; Buza N
Int J Gynecol Pathol; 2021 May; 40(3):263-271. PubMed ID: 32897955
[TBL] [Abstract][Full Text] [Related]
15. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.
McAlpine JN; Wiegand KC; Vang R; Ronnett BM; Adamiak A; Köbel M; Kalloger SE; Swenerton KD; Huntsman DG; Gilks CB; Miller DM
BMC Cancer; 2009 Dec; 9():433. PubMed ID: 20003286
[TBL] [Abstract][Full Text] [Related]
16. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.
Buza N; Hui P
Genes Chromosomes Cancer; 2013 Dec; 52(12):1178-86. PubMed ID: 24123408
[TBL] [Abstract][Full Text] [Related]
17. HER2 Testing in Endometrial Serous Carcinoma: Time for Standardized Pathology Practice to Meet the Clinical Demand.
Buza N
Arch Pathol Lab Med; 2021 Jun; 145(6):687-691. PubMed ID: 32649220
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
Baselga J; Carbonell X; Castañeda-Soto NJ; Clemens M; Green M; Harvey V; Morales S; Barton C; Ghahramani P
J Clin Oncol; 2005 Apr; 23(10):2162-71. PubMed ID: 15800309
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges.
Buza N; Roque DM; Santin AD
Arch Pathol Lab Med; 2014 Mar; 138(3):343-50. PubMed ID: 24576030
[TBL] [Abstract][Full Text] [Related]
20. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice.
Buza N; English DP; Santin AD; Hui P
Mod Pathol; 2013 Dec; 26(12):1605-12. PubMed ID: 23765245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
